Clinical Trial Update: Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) [Phase 3]

View source ↗

Summary

Phase 3 LAS-MD-38 trial evaluated the efficacy, safety, and tolerability of aclidinium bromide in moderate-to-severe COPD; results have been posted following co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aclidinium bromide (Aclidinium bromide)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-12-09